Marcy Bolster to Scleroderma, Systemic
This is a "connection" page, showing publications Marcy Bolster has written about Scleroderma, Systemic.
Connection Strength
1.787
-
Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
Score: 0.226
-
Scleroderma renal crisis in pregnancy associated with massive proteinuria. Clin Exp Rheumatol. 2003 Jan-Feb; 21(1):114-6.
Score: 0.167
-
Assessment and management of scleroderma lung disease. Curr Opin Rheumatol. 1999 Nov; 11(6):508-13.
Score: 0.134
-
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
Score: 0.124
-
Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997 Apr; 40(4):743-51.
Score: 0.112
-
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
Score: 0.109
-
Corticosteroids: Friends and Foes. Rheum Dis Clin North Am. 2016 Feb; 42(1):xv-xvi.
Score: 0.103
-
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014 Aug; 44(1):55-62.
Score: 0.091
-
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
Score: 0.090
-
Lung disease in systemic sclerosis (scleroderma). Baillieres Clin Rheumatol. 1993 Feb; 7(1):79-97.
Score: 0.084
-
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis. 2012 Aug; 71(8):1335-42.
Score: 0.078
-
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
Score: 0.058
-
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
Score: 0.058
-
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
Score: 0.056
-
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
Score: 0.056
-
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
Score: 0.053
-
Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
Score: 0.052
-
Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
Score: 0.048
-
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
Score: 0.036
-
Scleroderma and related conditions. Med Clin North Am. 1997 Jan; 81(1):129-49.
Score: 0.028
-
Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-109-14.
Score: 0.024